Waltham, Massachusetts, USA, September 8, 2026
NanoMosaic has joined a Mass General Brigham-led consortium selected for the Advanced Research Projects Agency for Health (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, supporting a major effort to transform how genetic medicines are produced, analyzed and released. The consortium has been awarded up to $39.2 million as part of the GIVE program, which selected five multidisciplinary teams for up to $125 million in total funding. NanoMosaic will serve as an industry partner on the FUSE (Fast Unified Synthesis and Evaluation) project, contributing analytical technologies and software designed to integrate quality assurance, quality control and release testing directly into genetic medicine manufacturing.
ARPA-H Program Targets On-Demand Genetic Medicine Manufacturing
The FUSE project is being led by investigators from the Mass General Brigham Gene and Cell Therapy Institute and Massachusetts General Hospital and aims to develop a compact, automated manufacturing system capable of integrating the production and analysis of RNA medicines within a single platform. The broader objective is to establish a new model for producing genetic medicines closer to the patient, potentially reducing dependence on complex centralized manufacturing and distribution networks. Such an approach could be particularly important for personalized and individualized genetic medicines, where conventional large-scale manufacturing models may not be well suited to rapid or patient-specific production. The project reflects growing efforts across the biopharmaceutical sector to address manufacturing complexity as RNA therapies, cell therapies and gene therapies become increasingly sophisticated. Traditional manufacturing workflows can require multiple specialized processes for production, characterization, quality testing and release. By integrating these functions into an automated system, FUSE aims to create a more streamlined pathway for producing and evaluating genetic medicines in distributed or near-patient settings.
NanoMosaic to Lead Analytical and Quality Testing Engine
NanoMosaic will play a central role in developing the analytical and software engine for FUSE. The company’s responsibilities include integrating quality assurance (QA), quality control (QC) and release testing into the manufacturing workflow. This component is particularly relevant to biopharmaceutical manufacturing because genetic medicines require sophisticated analytical characterization to demonstrate that products meet predefined quality specifications before administration. NanoMosaic specializes in multiomic analytical technologies for cell and gene therapy development and manufacturing. Its NanoMosaic Tessie platform is designed for high-throughput biomarker detection, enabling simultaneous analysis of proteins and nucleic acids. The company says its technology can generate critical quality attributes (CQAs) relevant to cell and gene therapy development and manufacturing. Embedding analytical intelligence into the manufacturing process could potentially allow manufacturers to obtain quality information more rapidly and support automated product release decisions. For individualized medicines, where manufacturing timelines can be particularly important, reducing the time between production and quality assessment could have significant implications for accessibility and scalability.
Advertisement
FUSE Could Support Future Personalized Genetic Medicines
The ARPA-H investment highlights the U.S. government’s growing focus on technologies capable of making genetic medicines more accessible, scalable and responsive to individual patient needs. The FUSE approach combines expertise in RNA manufacturing, automation, analytical science and clinical translation, creating an integrated framework for decentralized production. For NanoMosaic, participation in the program expands its role beyond analytical technology development toward the broader manufacturing infrastructure required for next-generation genetic medicines. The project could ultimately help establish technologies for producing and evaluating medicines closer to where they are needed, while maintaining appropriate quality and release controls. Importantly, the FUSE program is a technology-development initiative rather than a clinical trial or regulatory approval of a genetic medicine. Its success will depend on demonstrating that automated, distributed manufacturing can consistently produce medicines meeting required quality standards. Nevertheless, the project represents a significant development in the emerging field of decentralized biomanufacturing, with potential implications for personalized RNA and other genetic medicine platforms.
Source: NanoMosaic press release
